Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. more
Time Frame | FATE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -30.94% | -2.27% | -0.57% |
1-Month Return | -15.67% | -3.96% | 1.21% |
3-Month Return | -54.48% | -9.7% | 7.57% |
6-Month Return | -51.33% | -3.37% | 11.45% |
1-Year Return | -31.72% | 3.71% | 28.48% |
3-Year Return | -96.26% | 3.8% | 29.52% |
5-Year Return | -90.26% | 39.78% | 90.66% |
10-Year Return | -49.03% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 10.68M | 31.43M | 55.85M | 96.30M | 63.53M | [{"date":"2019-12-31","value":11.09,"profit":true},{"date":"2020-12-31","value":32.64,"profit":true},{"date":"2021-12-31","value":57.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.97,"profit":true}] |
Cost of Revenue | 87.77M | 125.62M | 5.85M | 13.76M | 161.70M | [{"date":"2019-12-31","value":54.28,"profit":true},{"date":"2020-12-31","value":77.69,"profit":true},{"date":"2021-12-31","value":3.62,"profit":true},{"date":"2022-12-31","value":8.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (77.09M) | (94.19M) | 50.00M | 96.30M | (98.16M) | [{"date":"2019-12-31","value":-80.05,"profit":false},{"date":"2020-12-31","value":-97.81,"profit":false},{"date":"2021-12-31","value":51.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-101.93,"profit":false}] |
Gross Margin | (721.82%) | (299.64%) | 89.52% | 100.00% | (154.51%) | [{"date":"2019-12-31","value":-721.82,"profit":false},{"date":"2020-12-31","value":-299.64,"profit":false},{"date":"2021-12-31","value":89.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-154.51,"profit":false}] |
Operating Expenses | 111.41M | 159.52M | 272.84M | 404.69M | 254.04M | [{"date":"2019-12-31","value":27.53,"profit":true},{"date":"2020-12-31","value":39.42,"profit":true},{"date":"2021-12-31","value":67.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":62.78,"profit":true}] |
Operating Income | (100.73M) | (128.09M) | (216.99M) | (308.39M) | (190.51M) | [{"date":"2019-12-31","value":-10072700000,"profit":false},{"date":"2020-12-31","value":-12808500000,"profit":false},{"date":"2021-12-31","value":-21699400000,"profit":false},{"date":"2022-12-31","value":-30838600000,"profit":false},{"date":"2023-12-31","value":-19051100000,"profit":false}] |
Total Non-Operating Income/Expense | 5.16M | (42.90M) | 6.15M | 32.51M | 45.23M | [{"date":"2019-12-31","value":11.4,"profit":true},{"date":"2020-12-31","value":-94.84,"profit":false},{"date":"2021-12-31","value":13.6,"profit":true},{"date":"2022-12-31","value":71.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (98.15M) | (173.39M) | (212.15M) | (281.72M) | (160.93M) | [{"date":"2019-12-31","value":-9814900000,"profit":false},{"date":"2020-12-31","value":-17338700000,"profit":false},{"date":"2021-12-31","value":-21215100000,"profit":false},{"date":"2022-12-31","value":-28172100000,"profit":false},{"date":"2023-12-31","value":-16092800000,"profit":false}] |
Income Taxes | (441.00K) | (3.09M) | (5.85M) | (26.66M) | 18.11M | [{"date":"2019-12-31","value":-2.43,"profit":false},{"date":"2020-12-31","value":-17.04,"profit":false},{"date":"2021-12-31","value":-32.3,"profit":false},{"date":"2022-12-31","value":-147.21,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (97.71M) | (170.30M) | (206.30M) | (255.06M) | (179.04M) | [{"date":"2019-12-31","value":-9770800000,"profit":false},{"date":"2020-12-31","value":-17030000000,"profit":false},{"date":"2021-12-31","value":-20630100000,"profit":false},{"date":"2022-12-31","value":-25505600000,"profit":false},{"date":"2023-12-31","value":-17904210500,"profit":false}] |
Income From Continuous Operations | (98.15M) | (173.39M) | (212.15M) | (281.72M) | (173.17M) | [{"date":"2019-12-31","value":-9814900000,"profit":false},{"date":"2020-12-31","value":-17338700000,"profit":false},{"date":"2021-12-31","value":-21215100000,"profit":false},{"date":"2022-12-31","value":-28172100000,"profit":false},{"date":"2023-12-31","value":-17316900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (97.71M) | (170.30M) | (206.30M) | (255.06M) | (160.93M) | [{"date":"2019-12-31","value":-9770800000,"profit":false},{"date":"2020-12-31","value":-17030000000,"profit":false},{"date":"2021-12-31","value":-20630100000,"profit":false},{"date":"2022-12-31","value":-25505600000,"profit":false},{"date":"2023-12-31","value":-16092800000,"profit":false}] |
EPS (Diluted) | (1.43) | (2.08) | (2.23) | (2.91) | (1.64) | [{"date":"2019-12-31","value":-143,"profit":false},{"date":"2020-12-31","value":-208,"profit":false},{"date":"2021-12-31","value":-223,"profit":false},{"date":"2022-12-31","value":-291,"profit":false},{"date":"2023-12-31","value":-164,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
FATE | |
---|---|
Cash Ratio | 7.93 |
Current Ratio | 8.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
FATE | |
---|---|
ROA (LTM) | -22.11% |
ROE (LTM) | -46.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
FATE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
FATE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 17.55 |
P/B | 0.61 |
Price/FCF | NM |
EV/R | 1.58 |
EV/Ebitda | NM |
PEG | NM |
Fate Therapeutics Inc (FATE) share price today is $1.83
Yes, Indians can buy shares of Fate Therapeutics Inc (FATE) on Vested. To buy Fate Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FATE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Fate Therapeutics Inc (FATE) via the Vested app. You can start investing in Fate Therapeutics Inc (FATE) with a minimum investment of $1.
You can invest in shares of Fate Therapeutics Inc (FATE) via Vested in three simple steps:
The 52-week high price of Fate Therapeutics Inc (FATE) is $8.83. The 52-week low price of Fate Therapeutics Inc (FATE) is $1.82.
The price-to-earnings (P/E) ratio of Fate Therapeutics Inc (FATE) is
The price-to-book (P/B) ratio of Fate Therapeutics Inc (FATE) is 0.61
The dividend yield of Fate Therapeutics Inc (FATE) is 0.00%
The market capitalization of Fate Therapeutics Inc (FATE) is $248.29M
The stock symbol (or ticker) of Fate Therapeutics Inc is FATE